{"disease":{"id":"hemorrhagic-cystitis","name":"hemorrhagic cystitis"},"drugs":{"marketed":[{"drug_id":"mesna","indication_name":"Prevention of Chemotherapy-Induced Hemorrhagic Cystitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mesnex","generic_name":"MESNA","company_name":"Baxter","drug_phase":"marketed","molecular_target":"","drug_class":"mesna","quality_score":70,"revenue":null,"mechanism":"Mesnex works by binding to and neutralizing acrolein, a toxic byproduct of chemotherapy that causes hemorrhagic cystitis."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06198517","title":"Moxibustion for the Prevention of Hemorrhagic Cystitis After Allo-HSCT","phase":"NA","overall_status":"RECRUITING","enrollment_count":266,"lead_sponsor_name":"Yi Zhang","has_results":false},{"nct_id":"NCT04390113","title":"Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":97,"lead_sponsor_name":"AlloVir","has_results":true},{"nct_id":"NCT06241274","title":"Moxibustion in the Treatment of Hemorrhagic Cystitis After Allo-HSCT","phase":"NA","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT04696666","title":"Tolerability and Efficacy of INSTYLAN in Subjects With Moderate to Severe Hemorrhagic Cystitis","phase":"NA","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"LIDDE Therapeutics","has_results":false},{"nct_id":"NCT05348239","title":"Chlorophyllin Tablets for Urinary Bleeding Following Radiation Therapy for Cancers of Pelvic Organs","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":24,"lead_sponsor_name":"Tata Memorial Centre","has_results":false},{"nct_id":"NCT03129126","title":"The Safety, Tolerability and Efficacy of LP-10 in Subjects With Refractory Moderate to Severe Hemorrhagic Cystitis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":13,"lead_sponsor_name":"Lipella Pharmaceuticals, Inc.","has_results":false}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}